Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ludi Fan

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Diabetes Technology & Therapeutics|July 8, 2020
Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM Findings from the VIVID StudyThomas Blevins, Wendy Lane, David Rodbard, et al.
Journal of Diabetes and Its Complications|September 18, 2021
Individualized HbA1c target selection and achievement in the Multinational Observational Study Assessing Insulin Use (MOSA1c) type 2 diabetes studyA Enrique Caballero, Beth L Nordstrom, Birong Liao, et al.
Diabetes, Obesity & Metabolism|December 23, 2019
Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID studyGeorge Grunberger, Anuj Bhargava, Trang Ly, et al.
Diabetes Technology & Therapeutics|August 18, 2017
Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8Cynthia Harris, Thomas Forst, Tim Heise, et al.
Diabetes, Obesity & Metabolism|April 29, 2026
Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and ObesityAndreea Ciudin, Erin Johansson, Sarah Zimner-Rapuch, et al.
Current Medical Research and Opinion|May 4, 2023
Predictors of insulin pump initiation among people with type 2 diabetes from a US claims database using machine learningEmily R Hankosky, Michelle L Katz, Ludi Fan, et al.
Advances in Therapy|March 13, 2026
Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled TrialsAndreea Ciudin, Helene Sapin, Ludi Fan, et al.
Diabetes Research and Clinical Practice|May 2, 2024
Association between continuous glucose monitoring metrics and clinical outcomes in adults with type 1 diabetes in a real-world settingRobert Brett McQueen, Magaly Perez-Nieves, G Todd Alonso, et al.
Diabetes, Obesity & Metabolism|June 20, 2025
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetesAndreea Ciudin, Erin Johansson, Sarah Zimner-Rapuch, et al.
Current Medical Research and Opinion|October 27, 2020
Patient perspectives on the use of half-unit insulin pens by people with type 1 diabetes: a cross-sectional observational studyCarolina Piras de Oliveira, Beth D Mitchell, Ludi Fan, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Diabetes Technology & Therapeutics|July 8, 2020
Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM Findings from the VIVID StudyThomas Blevins, Wendy Lane, David Rodbard, et al.
Journal of Diabetes and Its Complications|September 18, 2021
Individualized HbA1c target selection and achievement in the Multinational Observational Study Assessing Insulin Use (MOSA1c) type 2 diabetes studyA Enrique Caballero, Beth L Nordstrom, Birong Liao, et al.
Diabetes, Obesity & Metabolism|December 23, 2019
Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID studyGeorge Grunberger, Anuj Bhargava, Trang Ly, et al.
Diabetes Technology & Therapeutics|August 18, 2017
Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8Cynthia Harris, Thomas Forst, Tim Heise, et al.
Diabetes, Obesity & Metabolism|April 29, 2026
Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and ObesityAndreea Ciudin, Erin Johansson, Sarah Zimner-Rapuch, et al.
Current Medical Research and Opinion|May 4, 2023
Predictors of insulin pump initiation among people with type 2 diabetes from a US claims database using machine learningEmily R Hankosky, Michelle L Katz, Ludi Fan, et al.
Advances in Therapy|March 13, 2026
Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled TrialsAndreea Ciudin, Helene Sapin, Ludi Fan, et al.
Diabetes Research and Clinical Practice|May 2, 2024
Association between continuous glucose monitoring metrics and clinical outcomes in adults with type 1 diabetes in a real-world settingRobert Brett McQueen, Magaly Perez-Nieves, G Todd Alonso, et al.
Diabetes, Obesity & Metabolism|June 20, 2025
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetesAndreea Ciudin, Erin Johansson, Sarah Zimner-Rapuch, et al.
Current Medical Research and Opinion|October 27, 2020
Patient perspectives on the use of half-unit insulin pens by people with type 1 diabetes: a cross-sectional observational studyCarolina Piras de Oliveira, Beth D Mitchell, Ludi Fan, et al.
Pageof 4